BBPvsSBIOETF Comparison
VS
Virtus LifeSci Biotech Products ETF (BBP) and ALPS Medical Breakthroughs ETF (SBIO) belong to the same industry segment: Tomorrow's Treatments. Both ETFs have the same top 3 sector exposures: and Healthcare. BBP is less expensive with a Total Expense Ratio (TER) of 0.34%, versus 0.5% for SBIO. BBP is up 21.54% year-to-date (YTD) with +$40M in YTD flows. SBIO performs better with 25.91% YTD performance, and +$41M in YTD flows. Run a side-by-side ETF comparison of BBP and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
BBP vs SBIO performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/27/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | BBP SBIO | +0.94%+0.08% | +15.67%+18.50% | +21.54%+25.91% | +56.59%+94.56% | +81.31%+116.75% | +94.15%+52.03% |
| Flows | BBP SBIO | +$10M+$17M | +$28M+$23M | +$40M+$41M | +$52M+$51M | +$55M+$20M | +$48M-$24M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | BBP SBIO | +26.32%+35.38% | +24.02%+30.61% | +24.33%+30.95% | +26.47%+33.95% |
| Max drawdown | BBP SBIO | -7.49%-10.73% | -9.59%-12.63% | -25.54%-42.12% | -37.61%-52.50% |
| Max drawdown duration | BBP SBIO | 44d43d | 48d60d | 292d331d | 586d1479d |
Trading data
BBP | SBIO | |
Last sale 7/28/2026 at 1:30 PM | $97.69 | $63.52 |
| Previous close 07/27/2026 | $97.26 | $64.48 |
| Consolidated volume 07/27/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
BBP | SBIO | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/28/2026 at 1:30 PM
Live
Closed
BBP | SBIO | |
|---|---|---|
| Last price | $97.69 | $63.52 |
| 1D performance | +0.45% | -1.49% |
| AuM | $96.94 M | $204.41 M |
| E/R | 0.34% | 0.5% |
Characteristics
BBP | SBIO | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | VIRTUS Investment Partners | ALPS |
| Benchmark | LifeSci Biotechnology Products Index | S-Network Medical Breakthroughs Index |
| N° of holdings | 66 | 103 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 16, 2014 | December 30, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
BBP
USA
89.11%
Other
10.89%
SBIO
USA
88.02%
Other
11.98%
Sectors
BBP
Healthcare
89.47%
Other
10.53%
SBIO
Healthcare
99.06%
Other
0.94%
Advertisement
Diversification
BBP
Total weight of top 15 holdings out of 15
87.15%
SBIO
Total weight of top 15 holdings out of 15
40.08%
Top 15 holdings
Data as of June 30, 2026
BBP
Verastem, Inc.
44.58%
Legend Biotech Corp.
41.98%
Agios Pharmaceuticals, Inc.
0.05%
BioCryst Pharmaceuticals, Inc.
0.05%
BioMarin Pharmaceutical, Inc.
0.05%
Rigel Pharmaceuticals, Inc.
0.05%
Crinetics Pharmaceuticals, Inc.
0.05%
Madrigal Pharmaceuticals, Inc.
0.05%
BioNTech SE
0.05%
Iovance Biotherapeutics, Inc.
0.05%
Rhythm Pharmaceuticals, Inc.
0.05%
Alnylam Pharmaceuticals, Inc.
0.05%
Incyte Corp.
0.05%
Sarepta Therapeutics, Inc.
0.05%
Omeros Corp.
0.05%
SBIO
Apogee Therapeutics, Inc.
4.36%
CG Oncology, Inc.
3.33%
Xenon Pharmaceuticals, Inc.
3.09%
Oruka Therapeutics, Inc.
3.05%
Dianthus Therapeutics, Inc.
2.83%
Travere Therapeutics, Inc.
2.80%
Definium Therapeutics, Inc.
2.73%
Veradermics, Inc.
2.72%
Edgewise Therapeutics, Inc.
2.32%
ACADIA Pharmaceuticals, Inc.
2.30%
Denali Therapeutics, Inc.
2.17%
Relay Therapeutics, Inc.
2.17%
NewAmsterdam Pharma Co. NV
2.10%
Crinetics Pharmaceuticals, Inc.
2.09%
Structure Therapeutics, Inc.
2.02%
Frequently asked questions about BBP and SBIO
How have the BBP and SBIO ETFs performed in 2026?
As of July 27, 2026, BBP is up 21.54% year-to-date (YTD), while SBIO has returned 25.91%. That puts SBIO better performer ahead so far this year.
Which ETF is attracting more investor money: BBP or SBIO?
Year-to-date, the BBP ETF saw +$40M in flows, compared to +$41M for SBIO.
Which ETF is more volatile: BBP or SBIO?
Over the past year, BBP had a volatility of 24.02%, while SBIO experienced 30.61%.
Which ETF is bigger: BBP or SBIO?
As of July 27, 2026, BBP holds $96.94 M in assets under management (AUM), while SBIO manages $204.41 M.
What sectors do the BBP and SBIO ETFs invest in?
BBP leans toward sectors like Healthcare. Meanwhile, SBIO focuses on Healthcare.
What are the top holdings of the BBP ETF and SBIO ETF?
BBP top holdings include Verastem, Inc., Legend Biotech Corp. and Agios Pharmaceuticals, Inc.. SBIO holds in its top three: Apogee Therapeutics, Inc., CG Oncology, Inc. and Xenon Pharmaceuticals, Inc..
Which ETF is more diversified: BBP or SBIO?
BBP holds 66 securities with 87.15% of its assets in the top 15. SBIO has 104 securities and a top 15 weight of 40.08%.
Advertisement
Latest news about BBP & SBIO
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Advertisement
Advertisement
